<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: The epidermal growth factor receptor (EGFR) is a tyrosine kinase (TK) involved in the <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> of many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types and may serve as an important therapeutic target (<z:chebi fb="0" ids="114785">erlotinib</z:chebi>, cetuximab) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001425'>Heterogeneity</z:hpo> of EGFR amplification and expression could represent a major drawback for anti-EGFR therapy </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was performed to determine the potential impact of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> on anti-EGFR therapy in Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (BAC) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Tissue microarray (<z:chebi fb="39" ids="18139,53050">TMA</z:chebi>) sections of 112 BAC and 45 lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> were analysed for EGFR amplification and expression using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) </plain></SENT>
<SENT sid="4" pm="."><plain>A subset of 20 samples was also sequenced for EGFR exons 18-21 and Kirsten rat <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homologue (KRAS) exons 2-3 mutations </plain></SENT>
<SENT sid="5" pm="."><plain>EGFR amplification was seen in seven (6.25%) of 112 interpretable BAC and typically high-level with more than 10-20 EGFR copies per <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell (EGFR/centromere 7 ratio &gt;3) </plain></SENT>
<SENT sid="6" pm="."><plain>EGFR amplification was associated with high pT, pN and poor prognosis (P = 0.0004) </plain></SENT>
<SENT sid="7" pm="."><plain>Identical EGFR amplification status was found in 29 primary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and 29 matched <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, FISH analysis of three to 16 large sections from <z:hpo ids='HP_0000001'>all</z:hpo> amplified BAC and corresponding <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> did not reveal any <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of EGFR amplification </plain></SENT>
<SENT sid="9" pm="."><plain>No EGFR mutation but one KRAS mutation was found </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The high level and homogeneity of EGFR amplification in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumours</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> suggests the potential therapeutic utility of anti-EGFR drugs in BAC </plain></SENT>
</text></document>